Vaccines for the treatment and prevention of zoonotic infections
The invention relates to compositions comprising a nucleic acid that encodes a peptide or a peptide that induces an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to vaccines comprising compositions and to method for treating and preventing an infection in animals and mammals such as humans.
1 . An immunogenic composition comprising a viral antigen of a pathogen containing an epitope that, upon administration to a human, a mammal or an animal, generates an immune response to the pathogen, wherein the viral antigen comprises a sequence selected from the group of sequences consisting of SEQ ID NOs. 109-111, 113-116, 120-131 and combinations thereof.
2 . The composition of claim 1 , which further comprises a sequence of an influenza virus antigen obtained or derived from an hemagglutinin (HA) protein, a neuraminidase (NA) protein, a matrix 1 (M1) protein, a matrix 2 (M2) protein, a matrix 2e (M2e) protein of an influenza virus, and/or a fragment, derivative, or modification thereof.
3 . The composition of claim 2 , which comprises multiple sequences of influenza virus antigens.
4 . The composition of claim 1 , further comprising T cell stimulating epitope obtained or derived from tetanus toxin, tetanus toxin heavy chain proteins, diphtheria toxoid, CRM, recombinant CRM, tetanus toxoid, Pseudomonas exoprotein A, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, Escherichia coli heat-labile toxin B subunit, Neisseria meningitidis outer membrane complex, Hemophilus influenzae protein D, Flagellin Fli C, Horseshoe crab Haemocyanin, and/or a fragment, derivative, or modification thereof.
5 . The composition of claim 4 , wherein the T cell stimulating epitope is at an N-terminus or a C-terminus of the antigen.
6 . The composition of claim 4 , which comprises multiple T cell stimulating epitopes.
7 . The composition of claim 1 , further comprising an adjuvant.
8 . The composition of claim 7 , wherein the adjuvant comprises Freund's adjuvant, army liposome formulation FQ (ALFQ), army liposome formulation QA (ALFQA), army liposome formulation A (ALFA), adjuvant system 3 (AS01), adjuvant system 01b (AS01b), a liposome adjuvant, saponin, lipid A, squalene, and/or modifications, derivatives and combinations thereof.
9 . The composition of claim 1 , which is a vaccine that treats or prevents a viral infection.
10 . An immunogenic composition comprising a viral antigen of a pathogen containing an epitope that, upon administration to a human, a mammal or an animal, generates an immune response to the pathogen, wherein the viral antigen consists essentially of the sequence of SEQ ID NO. 119.
11 . The composition of claim 10 , which further comprises a sequence of an influenza virus antigen obtained or derived from an hemagglutinin (HA) protein, a neuraminidase (NA) protein, a matrix 1 (M1) protein, a matrix 2 (M2) protein, a matrix 2e (M2e) protein of an influenza virus, and/or a fragment, derivative, or modification thereof.
12 . The composition of claim 11 , which comprises multiple sequences of influenza virus antigens.
13 . The composition of claim 10 , further comprising T cell stimulating epitope obtained or derived from tetanus toxin, tetanus toxin heavy chain proteins, diphtheria toxoid, CRM, recombinant CRM, tetanus toxoid, Pseudomonas exoprotein A, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, Escherichia coli heat-labile toxin B subunit, Neisseria meningitidis outer membrane complex, Hemophilus influenzae protein D, Flagellin Fli C, Horseshoe crab Haemocyanin, and/or a fragment, derivative, or modification thereof.
14 . The composition of claim 13 , wherein the T cell stimulating epitope is at an N-terminus or a C-terminus of the antigen.
15 . The composition of claim 13 , which comprises multiple T cell stimulating epitopes.
16 . The composition of claim 10 , further comprising an adjuvant.
17 . The composition of claim 16 , wherein the adjuvant comprises Freund's adjuvant, army liposome formulation FQ (ALFQ), army liposome formulation QA (ALFQA), army liposome formulation A (ALFA), adjuvant system 3 (AS01), adjuvant system 01b (AS01b), a liposome adjuvant, saponin, lipid A, squalene, and/or modifications, derivatives and combinations thereof.
18 . The composition of claim 10 , which is a vaccine that treats or prevents a viral infection.
19 . An immunogenic composition comprising a viral antigen of a pathogen containing an epitope that, upon administration to a human, a mammal or an animal, generates an immune response to the pathogen, wherein the viral antigen consists of the sequence selected from the group of sequences consisting of SEQ ID NOs. 109-111, 113-116, 119-131, and combinations thereof.